

# Giovanna Marrapese

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11069101/publications.pdf>

Version: 2024-02-01

14  
papers

2,990  
citations

759233

12  
h-index

1058476

14  
g-index

14  
all docs

14  
docs citations

14  
times ranked

4587  
citing authors

#	ARTICLE	IF	CITATIONS
1	Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. <i>Lancet Oncology</i> , The, 2005, 6, 279-286.	10.7	924
2	Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 738-746.	10.7	778
3	Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). <i>Cancer Discovery</i> , 2017, 7, 400-409.	9.4	647
4	Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer. <i>PLoS ONE</i> , 2009, 4, e7287.	2.5	241
5	Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2016, 108, .	6.3	111
6	HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer. <i>Oncologist</i> , 2019, 24, 1395-1402.	3.7	95
7	Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer. <i>British Journal of Cancer</i> , 2015, 113, 1730-1734.	6.4	65
8	Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2020, 19, 256-262.e2.	2.3	56
9	Entrectinib for the treatment of metastatic NSCLC: safety and efficacy. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 333-341.	2.4	26
10	Phase 1 open label, dose escalation study of RXDX101, an oral pan-trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2502-2502.	1.6	18
11	Pooled Analysis of Clinical Outcome of Patients with Chemorefractory Metastatic Colorectal Cancer Treated within Phase I/III Clinical Studies Based on Individual Biomarkers of Susceptibility: A Single-Institution Experience. <i>Targeted Oncology</i> , 2017, 12, 525-533.	3.6	15
12	TRKA expression and <i>NTRK1</i> gene copy number across solid tumours. <i>Journal of Clinical Pathology</i> , 2018, 71, 926-931.	2.0	12
13	EGFR FISH analysis in colorectal cancer as a tool in selecting patients for antiEGFR monoclonal antibodies therapy. <i>Oncology Reviews</i> , 2009, 3, 187-193.	1.8	1
14	Is Codon 13 KRAS Mutation Biologically Different from Codon 12 Mutation?. <i>Current Colorectal Cancer Reports</i> , 2012, 8, 272-276.	0.5	1